MEI Pharma Ownership
| MEIP Stock | USD 2.43 0.03 1.22% |
Shares in Circulation | First Issued 2002-06-30 | Previous Quarter 6.7 M | Current Value 6.7 M | Avarage Shares Outstanding 2.2 M | Quarterly Volatility 2.3 M |
MEI |
MEI Stock Ownership Analysis
About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MEI Pharma recorded a loss per share of 5.73. The entity last dividend was issued on the 16th of November 2023. The firm had 1:20 split on the 17th of April 2023. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about MEI Pharma contact Justin CPA at 858 369 7100 or learn more at https://meipharma.com.Besides selling stocks to institutional investors, MEI Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different MEI Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align MEI Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
MEI Pharma Quarterly Liabilities And Stockholders Equity |
|
MEI Pharma Insider Trades History
Only 1.31% of MEI Pharma are currently held by insiders. Unlike MEI Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against MEI Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of MEI Pharma's insider trades
MEI Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MEI Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MEI Pharma backward and forwards among themselves. MEI Pharma's institutional investor refers to the entity that pools money to purchase MEI Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 23.4 K | Susquehanna International Group, Llp | 2024-12-31 | 22.6 K | State Street Corp | 2024-12-31 | 17.8 K | Ubs Group Ag | 2024-12-31 | 11.2 K | Virtu Financial Llc | 2024-12-31 | 10.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.8 K | Newbridge Financial Services Group, Inc. | 2024-12-31 | 2 K | Group One Trading, Lp | 2024-12-31 | 2 K | Tower Research Capital Llc | 2024-12-31 | 1.4 K | Anson Funds Management Lp | 2024-12-31 | 1.1 M | Cable Car Capital Llc | 2024-12-31 | 611.4 K |
MEI Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MEI Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MEI Pharma Outstanding Bonds
MEI Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MEI Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MEI bonds can be classified according to their maturity, which is the date when MEI Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MUBAUH 37 07 NOV 49 Corp BondUS55276VAK89 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MTB 465 27 JAN 26 Corp BondUS55279HAV24 | View | |
| MTB 47 27 JAN 28 Corp BondUS55279HAW07 | View | |
| MFRS TRADERS TR Corp BondUS55279HAK68 | View | |
| US55279HAQ39 Corp BondUS55279HAQ39 | View | |
| US552704AF51 Corp BondUS552704AF51 | View |
MEI Pharma Corporate Filings
8K | 31st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 20th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.